Menopause weight gain: the scale is the wrong instrument

The Study of Women's Health Across the Nation followed women through the transition with repeated DXA body composition scans, which is what makes it possible to separate weight from what weight is made of. Its 2019 analysis in JCI Insight is the reference document here, and its abstract states the finding compactly: fat and lean mass increased prior to the transition; at the start of the transition, the rate of fat gain doubled and lean mass declined; gains and losses continued until 2 years after the final menstrual period; after that the trajectories decelerated to zero slope. And then the sentence that upends the popular account: weight climbed linearly during premenopause without acceleration at the transition.

The authors state the mechanism plainly: the rate of increase in the sum of fat mass and lean mass does not differ between premenopause and the transition, so there is no discernible change in the rate of weight gain at the start of the transition. Fat is going up faster and lean is coming down, and the two roughly cancel on the scale. Across an average transition of about 3.5 years, that works out to roughly 1.6 kg of fat gained and about 0.2 kg of lean mass lost.

A companion SWAN analysis looked at regional distribution in 380 women with DXA measures, with a racial and ethnic composition of 16 percent Black, 41 percent Japanese and 43 percent White. Android fat, meaning fat around the middle, increased by 1.21 percent per year before the transition and 5.54 percent per year during it. Visceral and gynoid fat began increasing at the transition, at 6.24 percent and 2.03 percent per year respectively.

Now the part that explains a common frustration. Waist girth grew during premenopause at 0.55 percent per year, during the transition at 0.96 percent, and postmenopause at 0.55 percent, and those rates were not statistically different from each other. So visceral fat, the depot most associated with metabolic risk, accelerated sharply at the transition while the number you get from a tape measure around your waist did not accelerate at all.

An earlier SWAN analysis found an absolute cumulative six-year increase in fat mass at midlife, and the American Heart Association's scientific statement describes the transition as a time of accelerating cardiovascular risk, with adverse alterations in body composition, lipids and lipoproteins, and measures of vascular health. That is why the composition change matters even when the scale is flat. Our guides to the metabolic numbers to know after 40 and cholesterol by age cover the measures that do move.

This is the most reassuring finding in the literature and the least reported. After the transition, annual change in the body composition measures decelerated to zero slope. The North American Menopause Society's 2022 position statement puts it in one sentence: by about 2 years after the final menstrual period, weight changes flatten. The transition is a phase with an end, not a new permanent trajectory.

NAMS also gives the figure most often quoted in this context and attributes it carefully: after controlling for body size and ethnicity, the average weight gain during midlife and the menopause transition is 1.5 lb per year. Note the framing. That is midlife and the transition together, not a menopause effect, and it is consistent with SWAN finding no change in slope.

Neither, on the evidence. A Cochrane review identified 22 randomized trials of hormone therapy and weight, pooling 21 of them, with searches completed in August 1998. It found no statistically significant difference in mean weight gain between unopposed estrogen users and non-users (0.66 kg, 95% CI -0.62 to 1.93), and none for estrogen plus progestogen (-0.47 kg, 95% CI -1.63 to 0.69). Its conclusion is that there is evidence of no effect on body weight, meaning these regimens do not cause extra weight gain beyond what is normally gained at menopause. The review had insufficient data to analyze waist-hip ratio, fat mass or skinfold thickness, and 24 further trials were awaiting assessment, so it is a partial picture.

NAMS states the other direction with its own evidence grade: hormone therapy may help attenuate abdominal adipose accumulation and weight gain associated with the transition, the effect is small, and it is Level II evidence, which is NAMS's label for limited or inconsistent scientific evidence.

Nor does hormone therapy meaningfully protect muscle. A meta-analysis of 12 randomized trials in 4,474 participants found hormone therapy users lost 0.06 kg less lean body mass than controls, not statistically significant (p=0.26), with GRADE quality rated low, and results unchanged across every stratification tested. The authors conclude that interventions other than hormone therapy should be considered for muscle retention. Our guide to strength training after 40 covers what those interventions look like.

One randomized trial addressed this population directly. The Women's Healthy Lifestyle Project enrolled 535 healthy premenopausal women aged 44 to 50 and randomized them to a five-year behavioral diet and physical activity program or an assessment-only control.

Two honest caveats. The trial ran from 1992 to 1999, so it predates every current pharmacological option, and its dietary prescription reflects 1990s low-fat guidance: 1,300 kcal per day at 25 percent total fat, with physical activity expenditure of 1,000 to 1,500 kcal per week. The generalisable finding is not the macronutrient split. It is that a sustained behavioral program through the transition roughly doubled the proportion of women who ended it no heavier than they started, and that long-term adherence was what distinguished those who maintained it.

Given what the composition data shows, the target that fits the physiology is not the scale. It is preserving lean mass while limiting fat gain, which means resistance training and adequate protein rather than restriction alone, and it means judging progress by strength, waist and metabolic markers rather than by a number that was never going to move much anyway. Our guide to protein after 40 covers where the intake evidence actually sits, including where the guidelines disagree with each other.

Rapid or unexplained weight change, weight loss you did not intend, or new symptoms such as marked fatigue, hair loss or temperature intolerance deserve assessment rather than a diet, since thyroid disease and other conditions imitate this picture. Our guide to a raised TSH covers one of them. If you are considering hormone therapy, weight should not be the reason, and the conversation is about symptoms, timing and personal risk. And since the transition is a period of accelerating cardiovascular risk, it is a sensible point to have blood pressure, lipids and glucose checked rather than assumed.